Detalles de la búsqueda
1.
Identification of risk factors for venous thromboembolism and validation of the Khorana score in patients with advanced lung cancer: based on the multicenter, prospective Rising-VTE/NEJ037 study data.
Int J Clin Oncol
; 28(1): 69-78, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36357710
2.
A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study.
Oncologist
; 27(11): 903-e834, 2022 11 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36181763
3.
Phase II study of carboplatin-paclitaxel alone or with bevacizumab in advanced sarcomatoid carcinoma of the lung: HOT1201/NEJ024.
Int J Clin Oncol
; 27(4): 676-683, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35092535
4.
Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B).
Int J Clin Oncol
; 27(1): 112-120, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34643820
5.
Safety and Efficacy of Nontuberculous Mycobacteria Treatment among Elderly Patients.
Medicina (Kaunas)
; 56(10)2020 Oct 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33023085
6.
A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101).
Int J Clin Oncol
; 23(6): 1060-1069, 2018 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-30027464
7.
Correction to: Osimertinib in poor performance status patients with T790Mpositive advanced nonsmallcell lung cancer after progression of first- and secondgeneration EGFRTKI treatments (NEJ032B).
Int J Clin Oncol
; 27(4): 823-824, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35257278
8.
A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study).
Eur J Cancer
; 197: 113469, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38061214
9.
Impact of the response to platinum-based chemotherapy on the second-line immune checkpoint inhibitor monotherapy in non-small cell lung cancer with PD-L1 expression ≤49%: a multicenter retrospective study.
Front Oncol
; 14: 1303543, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38344209
10.
[An elderly patient with large cell neuroendocrine carcinoma(LCNEC)for whom chemotherapy with irinotecan and split-dose cisplatin(CDDP)proved very effective].
Gan To Kagaku Ryoho
; 40(9): 1205-8, 2013 Sep.
Artículo
en Japonés
| MEDLINE | ID: mdl-24047780
11.
Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: Real-World Evidence from a Multicenter Retrospective Study.
Cancers (Basel)
; 15(5)2023 Feb 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-36900334
12.
Predictive Value of Modified Glasgow Prognostic Score and Persistent Inflammation among Patients with Non-Small Cell Lung Cancer Treated with Durvalumab Consolidation after Chemoradiotherapy: A Multicenter Retrospective Study.
Cancers (Basel)
; 15(17)2023 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37686634
13.
Real-world data on the efficacy and safety of immune-checkpoint inhibitors in elderly patients with non-small cell lung cancer.
Cancer Med
; 12(10): 11525-11541, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36999734
14.
Prophylactic treatment of dacomitinib-induced skin toxicities in epidermal growth factor receptor-mutated non-small-cell lung cancer: A multicenter, Phase II trial.
Cancer Med
; 12(14): 15117-15127, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37269194
15.
First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study.
Cancers (Basel)
; 15(20)2023 Oct 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-37894357
16.
Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study.
JTO Clin Res Rep
; 4(12): 100593, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-38046378
17.
Incidence of venous thromboembolism in advanced lung cancer and efficacy and safety of direct oral anticoagulants: a multicenter, prospective, observational study (Rising-VTE/NEJ037 study).
Ther Adv Med Oncol
; 14: 17588359221110171, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35898966
18.
A new risk-assessment tool for venous thromboembolism in advanced lung cancer: a prospective, observational study.
J Hematol Oncol
; 15(1): 40, 2022 04 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35379309
19.
Real-world outcomes of chemotherapy for lung cancer patients undergoing hemodialysis: A multicenter retrospective cohort study (NEJ-042).
Lung Cancer
; 172: 1-8, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35952438
20.
18F-FDG PET/CT for monitoring anti-PD-1 therapy in patients with non-small cell lung cancer using SUV harmonization of results obtained with various types of PET/CT scanners used at different centers.
Ann Nucl Med
; 35(11): 1253-1263, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34370219